{"id":4172,"date":"2019-08-01T09:25:50","date_gmt":"2019-08-01T09:25:50","guid":{"rendered":"https:\/\/aspree.org\/aus\/?p=4172"},"modified":"2021-08-02T08:05:34","modified_gmt":"2021-08-02T08:05:34","slug":"nih-funds-nih-funds-aspree-xt-extension-study","status":"publish","type":"post","link":"https:\/\/aspree.org\/aus\/nih-funds-nih-funds-aspree-xt-extension-study\/","title":{"rendered":"NIH funds ASPREE-XT (eXTension) study"},"content":{"rendered":"\r\n<h2 class=\"wp-block-heading\"><strong>Landmark study to assess long-term health risks and benefits of prior aspirin use in elderly<\/strong><\/h2>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n\r\n\r\n\r\n<p><em>PRESS RELEASE\u00a0<\/em><\/p>\r\n\r\n\r\n\r\n\r\n\r\n<ul>\r\n<li>Landmark ASPREE study extended for five years to track study participants for long-term health outcomes after discontinuing aspirin.<\/li>\r\n<li>ASPREE-XT will investigate the long-term health in people over 70 (65 years in the US) following conclusion of <a href=\"\/aus\/aspree-publishes-trial-results-in-new-england-journal-of-medicine-today\/\">ASPREE<\/a> (low-dose aspirin vs placebo) in 2017.<\/li>\r\n<li>Researchers will continue to monitor for cancer, dementia, cardiovascular health, physical disability, depression and frailty.<\/li>\r\n<li>ASPREE-XT will also investigate the impact that medical conditions, lifestyle, the environment and genetics have on health and ageing.<\/li>\r\n<li>More than 15,000 study participants in Australia and the US.<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p>Researchers at <a href=\"https:\/\/www.monash.edu\/medicine\/sphpm\" target=\"_blank\" rel=\"noreferrer noopener\">Monash University<\/a> and the US-based <a href=\"http:\/\/bermancenter.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">Berman Center for Outcomes and Clinical Research<\/a>, part of the Hennepin Healthcare Research Institute, are expanding on the landmark aspirin trial, ASPREE, with a five-year follow up study to investigate the long-term effects of low-dose aspirin on the health of older people.<\/p>\r\n\r\n\r\n\r\n<p>The world-first\u00a0<a href=\"\/aus\/about-the-aspree-project\">ASPREE-XT (eXTension) study<\/a>\u00a0will track the health of more than 15,000 participants in Australia and the US, following an average period of almost five years on daily low-dose aspirin or a placebo tablet in the ASPREE trial.<\/p>\r\n\r\n\r\n\r\n<p>Researchers will assess health impacts after prolonged aspirin use on cancer, dementia, cardiovascular health, physical disability, depression and other aspects of ageing including frailty.<\/p>\r\n\r\n\r\n\r\n<p>ASPREE-XT also aims to identify the impact that medical conditions, lifestyle, the environment and genetics have on health and ageing, providing an unprecedented window into an ageing population.<\/p>\r\n\r\n\r\n\r\n<p><a href=\"\/aus\/about-us\/\" target=\"_blank\" rel=\"noopener noreferrer\">Principal investigator<\/a> in Australia, Professor John McNeil, of Monash University\u2019s Department of Epidemiology and Preventive Medicine, said ASPREE-XT would contribute high quality research to understand factors that affect quality of life and independence for older people.<\/p>\r\n\r\n\r\n\r\n<p>\u201cASPREE-XT builds on many millions of individual items of health data collected in the ASPREE study, providing a rare opportunity to investigate the effects of aspirin and other factors on the health of older people,\u201d Professor McNeil said.<\/p>\r\n\r\n\r\n\r\n<p>\u201cImportantly, ASPREE-XT will also help identify factors that contribute to onset of disease in older people and explain why some people become frail and disabled while others do not.\u201d<\/p>\r\n\r\n\r\n\r\n<p>Professor McNeil said ASPREE-XT will be one of the largest observational studies conducted in Australia with the help of over 2000 <a href=\"\/aus\/about-us\/\" target=\"_blank\" rel=\"noopener noreferrer\">general practitioners<\/a> across south-eastern Australia.<\/p>\r\n\r\n\r\n\r\n<p>\u201cLife-expectancy has increased globally and ASPREE-XT will continue to answer questions of daily relevance for GPs caring for their older patients,\u201d Professor McNeil said.<\/p>\r\n\r\n\r\n\r\n<p>\u201cThe collection of this important health information is of great benefit to society, and through ASPREE-XT we are grateful that our participants continue to contribute data.\u201d<\/p>\r\n\r\n\r\n\r\n<p>ASPREE-XT is funded by the <a href=\"\/aus\/about-us\/funding-and-collaborators\">US National Institutes of Health<\/a>.<\/p>\r\n\r\n\r\n\r\n<blockquote class=\"wp-block-quote\">\r\n<p><strong><em>About ASPREE (ASPirin in Reducing Events in the Elderly)<\/em><\/strong><\/p>\r\n<cite><em>ASPREE was a world-first clinical trial of low-dose aspirin for primary prevention in the elderly. Trial findings published in the New England Journal of Medicine in September 2018 were adopted into the American College of Cardiology\/American Heart Association aspirin guidelines in March 2019.<\/em><\/cite><\/blockquote>\r\n\r\n\r\n\r\n<p>&nbsp;<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>Researchers at Monash University and the US-based Berman Center for Outcomes and Clinical Research, are expanding on the landmark aspirin trial, ASPREE, with a five-year follow-up study to investigate the long-term effects of low-dose aspirin on the health of older adults.<\/p>\n","protected":false},"author":2,"featured_media":6322,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"1200","footnotes":""},"categories":[17,36,18,16],"tags":[38,51],"_links":{"self":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/4172"}],"collection":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/comments?post=4172"}],"version-history":[{"count":23,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/4172\/revisions"}],"predecessor-version":[{"id":8286,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/posts\/4172\/revisions\/8286"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media\/6322"}],"wp:attachment":[{"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/media?parent=4172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/categories?post=4172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aspree.org\/aus\/wp-json\/wp\/v2\/tags?post=4172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}